Acknowledgments
The authors wish to thank staff and volunteers from the Pathology and Rheumatology departments at the James Cook University Hospital, Middlesbrough who made this study possible. We thank Immuno-Diagnostic Systems (Boldon, UK) for providing PINP and βCTX reagents for the iSYS analyser.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: JMvL has received a research grant, consultancy and speaker fees from Roche. SPT has received speaker fees from Ely Lilly.
Honorarium: None declared.
References
1. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013;11:201.10.1186/1479-5876-11-201Search in Google Scholar PubMed PubMed Central
2. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. for the IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391–420.10.1007/s00198-010-1501-1Search in Google Scholar PubMed
3. Stokes FJ, Ivanov P, Bailey LM, Fraser WD. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011;57:138–40.10.1373/clinchem.2010.157289Search in Google Scholar PubMed
4. Brandt J, Krogh TN, Jensen CH, Frederiksen JK, Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human Procollagen type I in relation to assay technology. Clin Chem 1999;45:47–53.10.1093/clinchem/45.1.47Search in Google Scholar
5. Seibel MJ, Lang M, Geilenkeuser W-J. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47:1443–50.10.1093/clinchem/47.8.1443Search in Google Scholar
6. Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 2010;21:439–45.10.1007/s00198-009-0974-2Search in Google Scholar PubMed PubMed Central
7. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, et al. National Bone Health Alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012;23:2425–33.10.1007/s00198-012-2049-zSearch in Google Scholar PubMed PubMed Central
8. Cavalier E, Carlisi A, Rousselle O, Ferrante N, Chapelle J-P. Analytical performance of the IDS-iSYS Crosslaps® (CTX-1) automated immunoassay. Scientific congresses and symposiums: posters 2012. Available from: http://hdl.handle.net/2268/127876. Accessed 14 April, 2013.Search in Google Scholar
9. Koivula M-K, Ruotsalainen V, Björkman M, Nurmenniemi S, Ikäheimo R, Savolainen K, et al. Difference between total and intact assays for N-terminal propeptide of type 1 procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem 2010;47:67–71.10.1258/acb.2009.009110Search in Google Scholar PubMed
10. Marin L, Koivula M-K, Jukkola-Vuorinen A, Leino A, Risteli J. Comparison of total and intact amino-terminal propeptide of type 1 procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 2011;48:447–51.10.1258/acb.2011.011040Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin/Boston
